Cargando…
Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma
Advances in the treatment of malignant pleural mesothelioma (MPM) have been disappointing, despite the apparent need for new therapeutic options for this rare and devastating cancer. Drug resistance is common and surgical intervention has brought benefits only to a subset of patients. MPM is a heter...
Autores principales: | Lapidot, Moshe, Saladi, Srinivas Vinod, Salgia, Ravi, Sattler, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776703/ https://www.ncbi.nlm.nih.gov/pubmed/35069219 http://dx.doi.org/10.3389/fphar.2021.806570 |
Ejemplares similares
-
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2020) -
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2021) -
Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2023) -
Gli as a Novel Therapeutic Target in Malignant Pleural Mesothelioma
por: Li, Hui, et al.
Publicado: (2013) -
Editorial: Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models
por: Lam, Sze-Kwan, et al.
Publicado: (2022)